The amino acid transporters SLC38A3–SLC38A5–SLC38A7 as novel anti-cancer therapeutic targets
- 1Laboratory of General Pathology, Department of Medicine and Surgery, University of Parma, Parma, Italy
- 2MRH - Microbiome Research Hub, University of Parma, Parma, Italy
Abstract
System N amino acid transporters SLC38A3 and SLC38A5 are carriers capable of mediating net inward or outward fluxes of substrates, such as glutamine, asparagine and histidine, coupled with Na+ symport and H+ antiport. The third member of the group, SLC38A7, principally exports glutamine and asparagine from lysosomes and its ion-coupling mechanism remains incompletely defined. Although historically less investigated than other amino acid transporters, emerging evidence reveals that System N carriers play diverse and context-dependent roles across several solid tumors and hematological malignancies. SLC38A3 can exert pro-tumor or tumor suppressive activities, displaying bidirectional transport and lineage-specific regulatory functions. SLC38A5 sustains macropinocytosis, pro-growth pathways, and antioxidant stress response conferring ferroptosis resistance. In addition, when expressed on stromal cells, it promotes amino acid exchanges within tumor microenvironment. SLC38A7 is expressed on lysosomal membranes to export proteolysis-derived amino acids and activates growth signaling. Together, evidence thus far available indicates that these transporters support metabolic plasticity, tumor progression, therapy resistance and microenvironmental remodeling in many types of cancers. This review summarizes recent advances in the comprehension of expression, regulation and functional relevance of System N transporters, highlighting their metabolic role in cancer and discussing their possible exploitation as emerging therapeutic targets.
Related
- Skin-Derived Non-Coding RNAs as Potential Biomarkers and Therapeutic Targets
- Plasma proteomic analysis identified potential therapeutic targets for pulmonary arterial hypertension
- Special Issue “Molecular Mechanisms and Therapeutic Targets in Skin Diseases”
- A genome-wide computational approach for therapeutic targets identification and synthetic peptide assembly enable rational vaccine design against Arcanobacterium haemolyticum
- AAV9 Gene Therapy for Ovarian Dysfunction and Reproductive Aging: Molecular Mechanisms, Therapeutic Targets, and Translational Perspectives
BibTeX
@article{madenis2026amino,
title = {{The amino acid transporters SLC38A3–SLC38A5–SLC38A7 as novel anti-cancer therapeutic targets}},
author = {Nektarios E. Madenis and Martina Chiu and Massimiliano G. Bianchi and Chiara Ughini and Mattia E. Castellucchio and Ovidio Bussolati and Giuseppe Taurino},
journal = {Frontiers in Molecular Biosciences},
year = {2026},
month = oct,
doi = {10.3389/fmolb.2026.1959729},
url = {https://doi.org/10.3389/fmolb.2026.1959729},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The amino acid transporters SLC38A3–SLC38A5–SLC38A7 as novel anti-cancer therapeutic targets
AU - Nektarios E. Madenis
AU - Martina Chiu
AU - Massimiliano G. Bianchi
AU - Chiara Ughini
AU - Mattia E. Castellucchio
AU - Ovidio Bussolati
AU - Giuseppe Taurino
PY - 2026
DA - 2026/10/13
JO - Frontiers in Molecular Biosciences
DO - 10.3389/fmolb.2026.1959729
UR - https://doi.org/10.3389/fmolb.2026.1959729
AB - System N amino acid transporters SLC38A3 and SLC38A5 are carriers capable of mediating net inward or outward fluxes of substrates, such as glutamine, asparagine and histidine, coupled with Na+ symport and H+ antiport. The third member of the group, SLC38A7, principally exports glutamine and asparagine from lysosomes and its ion-coupling mechanism remains incompletely defined. Although historically less investigated than other amino acid transporters, emerging evidence reveals that System N carriers play diverse and context-dependent roles across several solid tumors and hematological malignancies. SLC38A3 can exert pro-tumor or tumor suppressive activities, displaying bidirectional transport and lineage-specific regulatory functions. SLC38A5 sustains macropinocytosis, pro-growth pathways, and antioxidant stress response conferring ferroptosis resistance. In addition, when expressed on stromal cells, it promotes amino acid exchanges within tumor microenvironment. SLC38A7 is expressed on lysosomal membranes to export proteolysis-derived amino acids and activates growth signaling. Together, evidence thus far available indicates that these transporters support metabolic plasticity, tumor progression, therapy resistance and microenvironmental remodeling in many types of cancers. This review summarizes recent advances in the comprehension of expression, regulation and functional relevance of System N transporters, highlighting their metabolic role in cancer and discussing their possible exploitation as emerging therapeutic targets.
SN - 2296-889X
ER -